NVIDIA and Novo Nordisk Collaborate to Enhance Drug Discovery with AI
Darius Baruo Jun 11, 2025 09:59
NVIDIA partners with Novo Nordisk and DCAI to leverage AI technology in advancing drug discovery, utilizing the Gefion supercomputer for innovative pharmaceutical research.
NVIDIA has announced a significant partnership with Novo Nordisk, aiming to revolutionize drug discovery through the application of advanced artificial intelligence (AI) technologies. This collaboration, revealed at the NVIDIA GTC Paris event at VivaTech, aligns with Novo Nordisk's agreement with the Danish Center for AI Innovation (DCAI) to utilize the Gefion sovereign AI supercomputer, according to NVIDIA Newsroom.
AI-Driven Pharmaceutical Research
The collaboration is set to create customized AI models and agents to enhance early research and clinical development in drug discovery. By integrating NVIDIA's generative and agentic AI capabilities, the partnership seeks to accelerate the development of new pharmaceuticals. Rory Kelleher, Senior Director of Business Development for Life Sciences at NVIDIA, emphasized the transformative potential of AI in pharmaceutical R&D.
Technological Tools and Platforms
Novo Nordisk will leverage NVIDIA's suite of products, including the DGX SuperPOD, BioNeMo for generative AI-powered drug discovery, and NeMo microservices for building agentic workflows. Additionally, the Omniverse platform will be used to create simulation environments for developing physical AI applications. The focus will be on using AI to predict cellular responses and design molecules with drug-like properties.
Impact on Denmark's Healthcare Ecosystem
The Gefion supercomputer, operated by DCAI, is Denmark's flagship AI computing resource. It aims to lower barriers to advanced computing, enabling companies to pursue research and development in healthcare more effectively. Nadia Carlsten, CEO of DCAI, highlighted Gefion's role in addressing complex R&D challenges and unlocking new possibilities in pharmaceutical research.
Broader Applications and Innovations
Beyond drug discovery, the AI capabilities of Gefion are being utilized by startups like Teton, which is developing AI care companions for hospitals. These innovations aim to enhance patient monitoring and reduce the workload on healthcare professionals. Furthermore, efforts are underway to integrate Danish health data into a national analysis platform, which could revolutionize personalized treatment approaches.
For more detailed information, visit the NVIDIA Newsroom.
Image source: Shutterstock.jpg)
